Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1054 - Phase 2 study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): final results


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Site

Head and Neck Cancers


Ricard Mesia Nin


Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287


R. Mesia Nin1, P. Bossi2, A. Hansen3, C. Hsieh4, L.F. Licitra5, E.H. Tan6, P. Chen7, J. Miller8, L.L. Siu3, R. Haddad9

Author affiliations

  • 1 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 2 Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Medical Oncology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 4 Medical Oncology, China Medical University Hospital, 404 - Taichung/TW
  • 5 Head And Neck Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 6 Medical Oncology, National Cancer Center, Singapore/SG
  • 7 Biostatistics, Celgene Corporation, 07901 - Summit/US
  • 8 Oncology Clinical research And Development, Solid Tumor, Celgene - USA, 7920 - Basking Ridge/US
  • 9 Medical Oncology, Dana-Farber Cancer Institute, 2215 - Boston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1054


Second/third-line treatment (Tx) options are limited for pts with NPC. The efficacy and safety of CC-486 were assessed using Simon’s optimal 2-stage design in a phase 2 study. The predefined criterion for advancement to stage 2 (> 4 complete/partial responses) was not met. Here, we present final results from stage 1.


The single-arm, open-label study (NCT02269943) included pts with locally advanced/metastatic NPC who had ≥ 1 prior Tx, including ≥ 1 platinum-containing regimen. Pts received CC-486 300 mg orally on d 1-14 of a 21-d cycle until disease progression/unacceptable toxicity. The first 6 Asian-Pacific (AP) pts received CC-486 200 mg; if well tolerated, subsequent AP pts received 300 mg. Primary endpoints (per independent reviewer assessment): overall response rate, progression-free survival. Key secondary endpoints: overall survival, disease control rate, safety, pharmacokinetics (PK).


Median age of 36 enrolled pts was 54.0 y. Most were male (81%), had ECOG PS of ≤ 1 (97%), and had ≥ 2 prior systemic anticancer Tx (58%); 36% were AP. Pts received a median of 7.0 Tx cycles; 44% had ≥ 1 dose interruption and 39% had ≥ 1 dose reduction. 22 pts died: 1 on- and 21 post-Tx (> 28 d after last dose); 18 died due to disease complications. The table shows efficacy outcomes. PK analysis showed rapid absorption; exposure was comparable between doses. However, large inter-pt variability and small pt numbers did not allow definitive conclusions. All 36 safety-evaluable pts had ≥ 1 Tx-emergent adverse event (TEAE). Common TEAEs included vomiting (72%) and nausea (67%). Common grade 3/4 TEAEs included neutropenia (33%) and febrile neutropenia (11%).


The safety profile of CC-486 in pts with NPC was consistent with that in other solid tumors and of azacitidine. CC-486 monotherapy did not show sufficient clinical activity in the selected pt population to support further development in these pts.Table: 1071P

Primary EndpointsEfficacy-Evaluable Population (n = 25)
Overall response rate, n (%)3 (12)
Partial response3 (12)
Median progression-free survival (90% CI), mo4.7 (3.1 - 7.3)
Secondary Endpoints
Disease control rate, n (%)13 (52)
Median overall survival (90% CI), mo18 (14.8 - not reached)

Clinical trial identification


Legal entity responsible for the study

Celgene Corporation.


Celgene Corporation.

Editorial Acknowledgement

Medical writing assistance was provided by Rebecca Tweedell, PhD, MediTech Media, Ltd, funded by Celgene Corporation. All listed authors were fully responsible for all content and editorial decisions for this abstract.


R. Mesia Nin: Advisory role: AstraZeneca, Merck, MSD, BMS; Conferences fee: BMS, Merck. P. Bossi: Consultant/advisory and/or lectures: AstraZeneca, Kyowa Kyrin, Merck, Mundipharma, Roche; Travel coverage: Merck. L.F. Licitra: Consultant/advisory and/or lectures: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Debiopharm, Eisai, Merck Serono, MSD, Novartis, Roche, Sobi; Research funds to institution: AstraZeneca, Boehringer Ingelheim, Eisai, Merck Serono, MSD, Novartis, Roche; Travel coverage: Bayer, BMS, Debiopharm, Merck Serono, MSD, Sobi. P. Chen: Employee, stock units and stock options: Celgene. J. Miller: Employee, holds company stock: Celgene Pharmaceutical Company. L.L. Siu: Research funding (to institution): Celgene. R. Haddad: Consulting: BMS, Merck, Pfizer, Celgene, Genentech, AstraZeneca; Research support: BMS, Merck, Pfizer, Genentech, AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.